×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Senior Management
  • Victoria Blatter
    Victoria H. Blatter
    Senior Vice President, U.S. Government Affairs
  • Suzanne Blaug
    Suzanne Blaug
    Senior Vice President, Global Marketing and Commercial Development
  • Robert Bradway
    Robert A. Bradway
    Chairman and Chief Executive Officer
  • Judy Gawlik Brown
    Judy Gawlik Brown
    Senior Vice President, Global Business Services and Finance
  • Raymond Deshaies
    Senior Vice President, Discovery Research
  • Paul Eisenberg
    Paul R. Eisenberg
    Senior Vice President, U.S. Medical
  • Steven Galson
    Steven K. Galson
    Senior Vice President, Global Regulatory Affairs and Safety
  • Jonathan Graham
    Jonathan Graham
    Senior Vice President, General Counsel and Secretary
  • Laura Hamill
    Laura Hamill
    Senior Vice President, U.S. Commercial Operations
  • Sean Harper
    Sean E. Harper
    Executive Vice President, Research and Development
  • Anthony Hooper
    Anthony C. Hooper
    Executive Vice President, Global Commercial Operations
  • Lori Johnston
    Senior Vice President, Human Resources
  • Raymond Jordan
    Raymond C. Jordan
    Senior Vice President, Corporate Affairs
  • Corinne Legoff
    Corinne M. Le Goff
    Senior Vice President, Regional General Manager
  • Elliott Levy
    Elliott M. Levy
    Senior Vice President, Global Development
  • Robert Maroney
    Robert Maroney
    Senior Vice President, Manufacturing
  • Marrache Gilles
    Gilles Marrache
    Senior Vice President, Regional General Manager
  • Brian McNamee
    Brian M. McNamee
    Executive Vice President, Full Potential Initiatives
  • David Meline
    David W. Meline
    Executive Vice President and Chief Financial Officer
  • Alison Moore
    Alison Moore
    Senior Vice President, Process Development
  • Liam Murphy
    Liam Murphy
    Senior Vice President, Quality
  • Mike Nohaile
    Mike Nohaile
    Senior Vice President, Strategy, Commercialization & Innovation
  • Joshua Ofman
    Joshua J. Ofman
    Senior Vice President, Global Value, Access and Policy
  • Cynthia Patton
    Cynthia M. Patton
    Senior Vice President and Chief Compliance Officer
  • David Piacquad
    David A. Piacquad
    Senior Vice President, Business Development
  • Annalisa Pizzarello
    Annalisa Pizzarello
    Senior Vice President, Results Delivery Office
  • David Reese
    David M. Reese
    Senior Vice President, Translational Sciences
  • Esteban Santos
    Esteban Santos
    Executive Vice President, Operations
  • John Tsai
    Senior Vice President, Global Medical and Chief Medical Officer
Board of Directors
  • David Baltimore

    President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology

    David Baltimore is President Emeritus and Robert Andrews Millikan Professor of Biology at the California Institute of Technology, or Caltech. He received the Nobel Prize in Medicine as a co-recipient in 1975. Dr. Baltimore has been a director  of Regulus Therapeutics Inc., a biopharmaceutical company, since 2007, serving on its Compensation Committee and chairing its Nominating and Governance Committee, and is a member of its scientific advisory board. Dr. Baltimore has also been a member of the board of directors of Immune Design  Corp. (formerly Vaccsys), a clinical-stage immunotherapy company, since 2008, chairing its Nominating and Governance Committee, and is a member of its scientific advisory board. He was a director of BB Biotech, AG, a Swiss investment company, from 1994 to March 2011 and served as a director of MedImmune, Inc., a privately-held antibody formulation company, from 2003 until its acquisition by AstraZeneca plc, a pharmaceutical and biotechnology company, in 2007. In 2008, Dr. Baltimore became a founder of Calimmune, Inc., a privately-held clinical-stage gene therapy company, and served as Chairman of the board of directors until November 2015.

    Dr. Baltimore was President of Caltech from 1997 to 2006. Prior to this, he was a professor at the Massachusetts Institute of Technology, or MIT, and at The Rockefeller University where he also served as the President. During this time he was also the Chairman of the National Institutes of Health AIDS Vaccine Research Committee, a director and member of the Whitehead Institute for Biomedical Research, and a professor of microbiology and research professor of the American Cancer Society. He was a postdoctoral fellow at MIT and Albert Einstein College of Medicine and on the staff of The Salk Institute for Biological Studies. Dr. Baltimore has been awarded honorary degrees from numerous institutions, including Harvard, Yale and Columbia.

    Dr. Baltimore holds leadership roles in a number of scientific and philanthropic non-profit organizations, having been President of the American Association for the Advancement of Science and currently serving as a director and member of the Board of Scientific Counselors of the Broad Institute of MIT and Harvard. He is co-chair of The National Academy of Sciences Committee on Science, Technology and Law. Dr. Baltimore received an undergraduate degree from Swarthmore College and a doctorate from The Rockefeller University.

  • Robert A. Bradway

    Chairman and Chief Executive Officer, Amgen Inc.

    Robert A. Bradway is Amgen's chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company's president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.

    Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.

    He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is the chairman of the CEO Roundtable on Cancer, a non-profit organization comprised of executives founded to bring solutions to cancer treatment and prevention.

    Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard University.

  • François de Carbonnel

    Former Chairman of the Board and Director, Thomson S.A., and Director of Corporations

    François de Carbonnel is a director of corporations and corporate advisor. Mr. de Carbonnel was a member  of the group governance council of Mazars Group, a privately-held international  organization specializing  in audit, accountancy, tax, legal and advisory services, from December 2011 to January 2016. From 2004 to May 2015, Mr. de Carbonnel was a director of Solocal Group (formerly known as Pages Jaunes S.A.), a French company which offers online content, advertising solutions and transactional services, and served as Chairman of the Remuneration and Appointments Committee.

    From 2004 until October 2013, Mr. de Carbonnel was a director of a number of funds managed by Ecofin, a privately-held investment management firm. Mr. de Carbonnel was a director of Thomson S.A., a French multimedia corporation, from  2007 to January 2010, serving as Chairman of the Audit Committee throughout his tenure, and as non-executive Chairman of the Board from April 2008 to April 2009. Mr. de Carbonnel was a director of Quilvest S.A., a Luxembourg  company which provides wealth management and private equity services, from 2006 to 2013.

    Mr. de Carbonnel was a Senior Advisor of the Global Corporate and Investment Bank of Citigroup from 2004 to 2006, and a Managing Director from 1999 to 2004. He was the Chairman and Chief Executive Officer of Midial S.A., a French listed company, from 1994 to 1998, Chairman of General Electric Capital SNC from 1996 to 1998. He was a corporate Vice President of General Electric Company and President of General Electric Capital-Europe from 1990 to 1992, President of Strategic Planning Associates, an international consulting company, from 1981 to 1990 and Vice President of Boston Consulting Group from 1971 to 1981. He is a member emeritus of the Business Board of Advisors of the Carnegie Mellon Tepper School of Business. Mr. de Carbonnel is a French citizen and resides in Europe. Mr. de Carbonnel received an engineering diploma from the Ecole Centrale de Lyon, a master in economics from Lyon Université and a master of sciences degree from the Tepper School of Business at Carnegie Mellon University.

  • Robert A. Eckert  (Lead Independent Director)

    Chairman Emeritus, Mattel, Inc.

    Robert A. Eckert has been an Operating Partner at Friedman Fleischer & Lowe, a private equity firm, since September 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacture and marketing company, having held this position from 2000 through December 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992.

    Mr. Eckert has been a director of McDonald's Corporation, a company which franchises and operates McDonald's restaurants in the global restaurant industry, since 2003, serving as the Chair of the Public Policy and Strategy Committee and a member of the Executive and Governance Committees. Mr. Eckert was a director of Smart & Final Stores, Inc., a warehouse store, from May 2013 until July 2014 prior to it becoming a publicly-traded company. Mr. Eckert also has served as a director of Levi Strauss & Co., a privately-held jeans and casual wear manufacturer, since 2010. He was appointed director of Eyemart Express Holdings LLC, a privately-held eyewear retailer and portfolio company of Friedman Fleischer & Lowe, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona. Mr. Eckert received an undergraduate degree from the University of Arizona and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

  • Greg C. Garland

    Chairman and Chief Executive Officer, Phillips 66

    Greg C. Garland is the Chairman and Chief Executive  Officer of Phillips 66, an energy manufacturing and logistics company with midstream, chemical, refining and marketing and specialties businesses created through the repositioning of ConocoPhillips, having held this position since April 2012. Mr. Garland chairs the Executive Committee of Phillips 66. Prior to Phillips 66, Mr. Garland served as Senior Vice President, Exploration and Production, Americas of ConocoPhillips from 2010 to April 2012. He was President and Chief Executive Officer of Chevron Phillips Chemical Company (now a joint venture between Phillips 66 and Chevron) from 2008 to 2010 and Senior Vice President, Planning and Specialty Chemicals from 2000 to 2008. Mr. Garland served in various positions at Phillips Petroleum Company from 1980 to 2000. Mr. Garland is a member of the Engineering Advisory Board for Texas A&M University. Mr. Garland received an undergraduate degree from Texas A&M University.

  • Fred Hassan

    Partner and Managing Director, Warburg Pincus LLC

    Fred Hassan has been Partner and Managing Director at Warburg Pincus LLC, a global private equity investment institution, since 2011 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of Pharmacia Corporation, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of Pharmacia Corporation from its creation in 2000 as a result of the merger of Pharmacia & Upjohn, Inc. with Monsanto Company. He was President and Chief Executive Officer of Pharmacia & Upjohn, Inc. beginning in 1997. Mr. Hassan previously held senior positions with Wyeth (formerly known as American Home Products), including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at Sandoz Pharmaceuticals and headed its U.S. pharmaceuticals businesses.

    Mr. Hassan has been a director of Time Warner Inc., a media company, since 2009, serving on  its Nominating  and  Governance  and  Compensation  and  Human  Development Committees; and Intrexon Corporation, a synthetic biology company, since June 2016. Mr. Hassan was a director of Avon Products, Inc., a manufacturer and marketer of beauty and related products, from 1999 until 2013 and served on its Compensation and Management Development, Nominating and Corporate Governance and Audit Committees, as lead independent director from 2009 to 2012, and Chairman of the Board between January and April 2013. Mr. Hassan was Chairman of the Board of Bausch & Lomb, from 2010 until its acquisition by Valeant Pharmaceuticals International, Inc., a pharmaceutical company, in 2013. Mr. Hassan served on the board of directors and Compensation and Audit Committees of Valeant Pharmaceuticals International, Inc. between August 2013 and May 2014. Mr. Hassan received an undergraduate degree from Imperial College of Science and Technology, University of London and a master's degree in business administration from Harvard Business School.

  • Rebecca M. Henderson

    John and Natty McArthur University Professor, Harvard University

    Rebecca M. Henderson has been the John and Natty McArthur University Professor at Harvard University since 2011. From 2009 to 2011, Dr. Henderson served as the Senator John Heinz Professor of Environmental Management at Harvard Business School. Prior to this, she was a professor of management at the Massachusetts Institute of Technology, or MIT, for 21 years, having been the Eastman Kodak LFM Professor of Management since 1999. Since  1995, she  has  also  been  a Research Associate at the National Bureau of Economic Research. She specializes in technology strategy and the broader strategic problems faced by companies in high technology industries.

    Dr. Henderson has been a director of IDEXX Laboratories, Inc., a company which provides diagnostic and information technology-based products and services for veterinary, food and water applications, since 2003, chairing its Finance Committee  and serving  on its Nominating and Governance Committee. Dr. Henderson has also served as a director of the Ember  Corporation,  a  privately-held  semiconductor  chip manufacturer,  and  on its Compensation Committee, from 2001 to July 2009. She has further been a director of Linbeck Construction Corporation, a privately-held facility solutions company, from 2000 until 2004. Dr. Henderson has published articles, papers and reviews in a range of scholarly journals. Dr. Henderson received an undergraduate degree from MIT and a doctorate from Harvard University.

  • Frank C. Herringer

    Retired Chairman and CEO, Transamerica Corporation

    Frank C. Herringer has been a director of the Board of Transamerica Corporation, a financial services company, since 1986, serving as Chairman of the board of directors from 1995 to December 2015. Mr. Herringer was an executive with Transamerica for 20 years, including its Chief Executive Officer from 1991 until its acquisition by Aegon N.V., a life insurance, pensions and asset management company, in 1999, subsequently serving on Aegon's Executive Board for one year. Mr. Herringer was a director   of Aegon U.S. Holding Corporation from 1999 until its merger into Transamerica Corporation in December 2015.

    Mr. Herringer has been a director of The Charles Schwab Corporation, a brokerage and banking company, since 1996, serving on its Compensation Committee and chairing its Nominating and Corporate Governance Committee. Mr. Herringer is a member of the Board of Trustees of the California Pacific Medical Center Foundation, a not-for-profit organization which develops philanthropic resources for the California Pacific Medical Center, a privately- held, not-for-profit academic medical center, since 2013.  Mr. Herringer was a director of Safeway Inc., a food and drug retailer, from 2008 until January 2015, serving on its Executive Compensation and Executive Committees and chairing  its Nominating and Corporate Governance Committee. Mr. Herringer was a director  of Cardax, Inc., a biotechnology company, from 2014 to April 2015, serving on its Compensation Committee and chairing its Governance and Nominating Committee, and was a director of its parent company, Cardax Pharmaceuticals, Inc., from 2006 until April 2015. From 2002 to 2005, Mr. Herringer was a director of AT&T Corporation, and a member of its Audit and Compensation Committees. In 2004, Mr. Herringer was named an Outstanding Director of the Year by the Outstanding Directors Exchange. Mr. Herringer received an undergraduate degree and master's degree in business administration from Dartmouth College.

  • Charles M. Holley, Jr.

    Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.

    Charles M. Holley, Jr. is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc., or Walmart, where he served from November 2010 to December 2015 and as Executive Vice President between January 1, 2016 and January 31, 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to November 2010. From December 2005 through December 2006, he served as Senior Vice President. Prior to that, Mr. Holley was Senior Vice President and Controller from 2003 to 2005. Mr. Holley served various roles in Wal-Mart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporation. He spent more than ten years with Ernst & Young LLP. Mr. Holley is an Independent Senior Advisor, U.S. CFO Program, Deloitte LLP, a privately-held provider of audit, consulting, tax, and advisory services, since July 2016.

    Mr. Holley serves on the Dean's Advisory Board for the McCombs School of Business at the University of Texas at Austin and the University of Texas Presidents' Development Board.

  • Tyler Jacks

    David H. Koch Professor of Biology, Massachusetts Institute of Technology and Director of the David H. Koch Institute for Integrative Cancer Research

    Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative  Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks has been an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994.

    Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since May 2009, and serves on its Strategy and Finance Committee and scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks has been a consultant scientific advisor to Epizyme, Inc., a biopharmaceutical company, since 2007, and has  served on the scientific advisory board of SQZ Biotech, a privately-held biotechnology company, since 2015. Dr. Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc. (formerly known as Equipoise Therapeutics), a privately-held biopharmaceutical company, in 2015 and serves as co-Chair of its scientific advisory board. He was appointed to the National Cancer Advisory Board, which  advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in October 2011. In April 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM  Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the Institute of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco.

  • Ellen J. Kullman

    Former President, Chair and Chief Executive Officer of E.I. du Pont de Nemours and Company

    Ellen J. Kullman is the former President, Chair and Chief Executive Officer of E.I. du Pont de Nemours and Company, or DuPont, a science and technology-based company, where she served from January 2009 to October 2015. Prior to this, Ms. Kullman served as President of DuPont from October 2008 to January 2009. From June 2006 through September 2008, she served as Executive Vice President of DuPont. Prior to that, Ms. Kullman was Group Vice President, DuPont Safety and Protection. Ms. Kullman has been a director of United Technologies Corporation, a technology products and services company, since 2011, serving on its Committee on Compensation and Executive Development and Chairing its Committee on Governance and Public Policy. Ms. Kullman has been a director of Goldman Sachs Group, Inc., an investment banking firm, since December 2016, serving on  its Compensation, Corporate Governance and Nominating, and Risk Committees. Ms. Kullman served as a director of General Motors, from 2004 to 2008, serving on its Audit Committee.

    Ms. Kullman has also served as a director of Carbon3D, Inc., a privately-held 3D printing company, since April 2016. Ms. Kullman has served on the Board of Trustees of Northwestern University since 2016 and on the Board of Overseers of Tufts University School of Engineering since 2006. She served as Chair of the US-China Business Council from 2013 to 2015. In 2016, Ms. Kullman joined the board of directors of Dell Technologies, a privately-held technology company, and the Temasek Americas Advisory Panel of Temasek Holdings (Private) Limited, a privately-held investment company based in Singapore. Ms. Kullman received a bachelor of science in mechanical engineering degree from Tufts  University  and a master's  degree from the Kellogg School of Management at Northwestern University.

  • Ronald D. Sugar

    Chairman Emeritus, Northrop Grumman Corporation

    Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporation, a global aerospace and defense company, having held these posts from 2003 through 2009.

    Dr. Sugar has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee; Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee; and of Air Lease Corporation, an aircraft leasing company, since 2010, chairing the Compensation Committee and serving on the Governance Committee. Since 2010, he has been a senior advisor to Ares Management LLC, a privately-held asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings (Private) Limited, a privately-held investment company based in Singapore. Dr. Sugar is a member of the National Academy of Engineering, trustee of the University of Southern California, member of the UCLA Anderson School of Management Board of Advisors, director of the Los Angeles Philharmonic Association and national trustee of the Boys and Girls Clubs of America.

  • R. Sanders Williams

    President of Gladstone Institutes and Robert W. and Linda L. Mahley Distinguished Professor of Medicine. Professor of Medicine, University of California, San Francisco

    R. Sanders Williams is President of Gladstone Institutes, a non-profit biomedical research enterprise, and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, both since 2010. He is also a Professor of Medicine at the University of California, San Francisco since 2010. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean  of the Duke-NUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center.

    Dr. Williams has been a director of the Laboratory Corporation of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit Committee and chairing the Quality and Compliance Committee. Dr. Williams was a director of Bristol- Myers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a non-profit institution that is distinct from Gladstone Institutes, since 2012 and on the board of directors of Exploratorium, a non-profit science museum and learning center located in San Francisco, since 2011. Dr. Williams was elected to the National Academy of Medicine in 2002. Dr. Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.

 

Scientific Advisory Boards

At Amgen, we recognize that innovation comes from many sources. The formation of the Amgen Scientific Advisory Boards formalizes our belief in engaging outside experts to help us theorize, test and spur our discovery and development processes forward. The Scientific Advisory Boards provide external scientific review of our research and development activities and assists management in making significant scientific judgments.

Co-Chairs

Elliott Sigal, MD, PhD
Former Chief Scientific Officer, Bristol-Myers Squibb
David Baltimore, PhD
President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology

Research Trends and Emerging Technologies

David J. Anderson, PhD
California Institute of Technology, Howard Hughes Medical Institute
Ron Evans, PhD
Salk Institute, Howard Hughes Medical Institute, National Academy of Sciences, Institute of Medicine
Richard O. Hynes, PhD, FRS
Koch Institute and Department of Biology at MIT, Howard Hughes Medical Institute, Broad Institute
John Kuriyan, PhD
University of California, Berkeley, Howard Hughes Medical Institute
Diane Mathis, PhD
Harvard Medical School, Broad Institute
Frank McCormick, PhD
University California San Francisco, Helen Diller Family Comprehensive Cancer Center
Ruslan Medzhitov, PhD
Yale University School of Medicine
Robert Tjian, PhD
Howard Hughes Medical Institute, University of California, Berkeley
Jonathan S. Weissman, PhD
Howard Hughes Medical Institute, University of California, San Francisco

Cardiovascular and Metabolic

Alfred L. George, Jr., MD
Northwestern University, Feinberg School of Medicine
Robert Harrington, MD
Arthur L. Bloomfield Professor of Medicine, Chairman of the Department of Medicine, Stanford University
David Alan Kass, MD
The Johns Hopkins University School of Medicine
Daniel P. Kelly, MD
Perelman School of Medicine, University of Pennsylvania
Peter Libby, MD
Harvard Medical School, Brigham and Women's Hospital, Division of Cardiovascular Medicine
Jeff D. Molkentin, PhD
Cincinnati Children's Hospital Medical Center
Stan Nattel, MD
Université de Montréal, McGill, Montréal Heart Institute
Jorge Plutzky, MD
Brigham and Women's Hospital, Division of Cardiovascular Medicine
Gerald M. Reaven, MD
Stanford School of Medicine
Alan R. Tall MB, BS
Tilden-Weger-Bieler Professor of Medicine, Head of the Division of Molecular Medicine, Columbia University
Gordon Tomaselli, MD
The Johns Hopkins University School of Medicine

Immuno-Oncology

James P Allison, PhD
MD Anderson Cancer Center
Mark M. Davis, PhD
Stanford School of Medicine
Keith Flaherty, MD
Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital, Harvard Medical School
Siwen Hu-Lieskovan, MD, PhD
Universtiy of California at Los Angeles Medical Center
Dirk Jager, PhD
Managing Director, NCT Heidelberg
Robert Negrin, MD
Stanford School of Medicine
Drew Pardoll, MD, PhD
The Johns Hopkins University School of Medicine
Antoni Ribas, MD, PhD
University of California at Los Angeles Medical Center
Ton Schumacher, PhD
Netherlands Cancer Institute
Benoit Van den Eynde, MD, PhD
Universtiy of California at Los Angeles Medical Center
Jedd Wolchok, MD, PhD
Memorial Sloan Kettering Cancer Center

Neuroscience

Steven T DeKosky, MD
University of Florida College of Medicine
Peter Goadsby, MD, PhD
University of California at San Franciso School of Medicine
Michael Greenberg, PhD
Harvard Medical School
John C Mazziotta, MD, PhD
Resnick Neuropsychiatric Hospital at UCLA, Ronald Reagan UCLA Medical Center
David G. Morgan, PhD
University of South Florida Department of Molecular Pharmacology and Physiology
Frank Porreca, PhD
The University of Arizona Cancer Center
Carla Shatz, PhD
Stanford School of Medicine
Irene Tracey, PhD
University of Oxford
Linda Van Eldik, PhD
University of Kentucky
Stephen Waxman, MD, PhD
Yale School of Medicine
×